TY - JOUR
T1 - MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas
AU - Ferreri, A. J M
AU - Dell'Oro, S.
AU - Foppoli, M.
AU - Bernardi, M.
AU - Brandes, A. A.
AU - Tosoni, A.
AU - Montanari, M.
AU - Balzarotti, M.
AU - Spina, M.
AU - Ilariucci, F.
AU - Zaja, F.
AU - Stelitano, C.
AU - Bobbio, F.
AU - Corazzelli, G.
AU - Baldini, L.
AU - Ponzoni, M.
AU - Picozzi, P.
AU - Cappio, F. Caligaris
AU - Reni, M.
PY - 2006/5
Y1 - 2006/5
N2 - The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ± 7%) was obtained.
AB - The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ± 7%) was obtained.
UR - http://www.scopus.com/inward/record.url?scp=33646711027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646711027&partnerID=8YFLogxK
U2 - 10.1212/01.wnl.0000210464.94122.e1
DO - 10.1212/01.wnl.0000210464.94122.e1
M3 - Article
C2 - 16682682
AN - SCOPUS:33646711027
VL - 66
SP - 1435
EP - 1438
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 9
ER -